Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer

Breast Cancer Research and Treatment

Volumn 98, Issue 3, 2006, Pages 295-301

  Xia, Wei Ya ^a   Lien, Huang Chun ^b   Wang, Shao Chun ^a   Pan, Yung ^a   Sahin, Aysegul ^a   Kuo, Yau Hung ^b   Chang, King Jeng ^b   Zhou, Xin ^a   Wang, Hongying ^a   Yu, Zhengming ^a   Hortobagyi, Gabriel ^a   Shi, Dar Ren ^c   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FUDAN UNIVERSITY   (China)

Author keywords

Breast cancer; ETS; HER 2 neu; PEA3; Tyrosine kinase receptor

Indexed keywords

TRANSCRIPTION FACTOR PEA3;

ADULT; AGED; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CARCINOGENESIS; CORRELATION ANALYSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE NEU; ONCOGENE PEA3; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; TUMOR GROWTH; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; MIDDLE AGED; MODELS, STATISTICAL; PROGNOSIS; RECEPTOR, ERBB-2; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 33746909048     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9162-7     Document Type: Article

References (30)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
3. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985
4. Yu D: Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 28(5 Suppl 16): 12-17, 2001
5. Spigel DR, Burstein HJ: HER2 overexpressing metastatic breast cancer. Curr Treat Options Oncol 3: 163-174, 2002
6. Wang SC, Hung MC: HER2 overexpression and cancer targeting. Semin Oncol 28(5 Suppl 16): 115-124, 2001
7. Xin JH, Cowie A, Lachance P, Hassell JA: Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells. Genes Dev 6: 481-496, 1992
8. Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY, Yu Z, Zhang S, Miller S, Huang L, Hung MC: The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 6: 189-195, 2000
9. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A, Hassell JA: HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15: 1513-1525, 1997
10. El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC: Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem 279: 20794-20806, 2004
11. Fleming FJ, Myers E, Kelly G, Crotty TB, McDermott EW, O'Higgins NJ, Hill AD, Young LS: Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol 57: 1069-1074, 2004
12. Davidson B, Goldberg I, Tell L, Vigdorchik S, Baekelandt M, Berner A, Kristensen GB, Reich R, Kopolovic J: The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin Exp Metastasis 21: 191-199, 2004
13. Kinoshita J, Kitamura K, Tanaka S, Sugimachi K, Ishida M, Saeki H: Clinical significance of PEA3 in human breast cancer. Surgery 131(1 Suppl): S222-S225, 2002
14. Weigelt B, Peterse JL, vant' Veer LJ: Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591-602, 2005
15. Karlan BY, Jones J, Slamon DJ, Lagasse LD: Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol Oncol 53: 70-77, 1994
16. Miller SJ, Xing X, Xi L, Hung MC: Identification of a specific DNA region required for enhanced transcription of HER2/neu in the MDA-MB453 breast cancer cell line. DNA Cell Biol 15: 749-757, 1996
17. Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher FJ, 3rd, Thor AD, Benz CC: Ets regulation of the erbB2 promoter. Oncogene 19: 6490-6502, 2000
18. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC: A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 13: 1701-1707, 1996
19. Chen H, Hung MC: Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene. J Biol Chem 272: 6101-6104, 1997
20. Yu D, Suen TC, Yan DH, Chang LS, Hung MC: Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA 87: 4499-4503, 1990
21. Fauquette V, Perrais M, Cerulis S, Jonckheere N, Ducourouble MP, Aubert JP, Pigny P, Van Seuningen I: The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells. Biochem J 386: 35-45, 2005
22. Menendez JA, Lupu R, Colomer R: Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/ neu-overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res Treat 84: 183-195, 2004
23. Menendez JA, Vellon L, Lupu R: Antitumoral actions of the antiobesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 16: 1253-1267, 2005
24. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428, 1998
25. Hapke S, Gawaz M, Dehne K, Kohler J, Marshall JF, Graeff H, Schmitt M, Reuning U, Lengyel E: beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol 21: 2118-2132, 2001
26. Preissner KT, Kanse SM, Chavakis T, May AE: The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: implications for cardiovascular function. Basic Res Cardiol 94: 315-321, 1999
27. Blasi F: Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 82: 298-304, 1999
28. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM: Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 8: 27-34, 2002
29. Iwasaki M, Nishikawa A, Akutagawa N, Fujimoto T, Teramoto M, Sakaguchi Y, Kato H, Ito M, Yoshida K, Kudo R: E1AF/PEA3 reduces the invasiveness of SiHa cervical cancer cells by activating serine proteinase inhibitor squamous cell carcinoma antigen. Exp Cell Res 299: 525-532, 2004
30. Guerra-Vladusic FK, Vladusic EA, Tsai MS, Lupu R: Signaling molecules implicated in heregulin induction of growth arrest and apoptosis. Oncol Rep 8: 1203-1214, 2001